DD264924A5 - Verfahren zur herstellung von pyrimidin-nucleosiden - Google Patents

Verfahren zur herstellung von pyrimidin-nucleosiden Download PDF

Info

Publication number
DD264924A5
DD264924A5 DD87310427A DD31042787A DD264924A5 DD 264924 A5 DD264924 A5 DD 264924A5 DD 87310427 A DD87310427 A DD 87310427A DD 31042787 A DD31042787 A DD 31042787A DD 264924 A5 DD264924 A5 DD 264924A5
Authority
DD
German Democratic Republic
Prior art keywords
group
compound
hydrogen
formula
hydroxy
Prior art date
Application number
DD87310427A
Other languages
German (de)
English (en)
Inventor
Saad G Rahim
Dorothy J M Purifoy
Original Assignee
��������@��������@����������@���k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ��������@��������@����������@���k�� filed Critical ��������@��������@����������@���k��
Publication of DD264924A5 publication Critical patent/DD264924A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Silicon Polymers (AREA)
DD87310427A 1986-12-15 1987-12-14 Verfahren zur herstellung von pyrimidin-nucleosiden DD264924A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868629892A GB8629892D0 (en) 1986-12-15 1986-12-15 Antiviral compounds

Publications (1)

Publication Number Publication Date
DD264924A5 true DD264924A5 (de) 1989-02-15

Family

ID=10609013

Family Applications (2)

Application Number Title Priority Date Filing Date
DD87310427A DD264924A5 (de) 1986-12-15 1987-12-14 Verfahren zur herstellung von pyrimidin-nucleosiden
DD87320503A DD274766A5 (de) 1986-12-15 1987-12-14 Verfahren zur herstellung einer pharmazeutischen formulierung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DD87320503A DD274766A5 (de) 1986-12-15 1987-12-14 Verfahren zur herstellung einer pharmazeutischen formulierung

Country Status (30)

Country Link
US (1) US5079235A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP0417560A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPS63165397A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR880007521A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN87108265A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE88713T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU601529B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1319143C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (3) CS275402B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (2) DD264924A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3785651T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK654287A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2054693T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (2) FI875487A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB8629892D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (4) HU202112B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (2) IE930471L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL95141A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2064B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LV (1) LV5273A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MC (1) MC1882A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9203216A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO167576C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ222898A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (2) PH24104A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL160321B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT86356B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2036199C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SU (1) SU1731064A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA879382B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598946B2 (en) * 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US4954485A (en) * 1987-10-20 1990-09-04 Sanyo-Kokusaku Pulp Co., Ltd. 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
US5006646A (en) * 1989-02-22 1991-04-09 Yuki Gosei Kogyo Co., Ltd. Process for preparing 2'-deoxy-5-trifluoromethyl-beta-uridine
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
GB9012899D0 (en) * 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
GB9014618D0 (en) * 1990-06-30 1990-08-22 Wellcome Found Process for the preparation of pyrimidine nucleosides
SG49855A1 (en) 1990-07-19 1998-06-15 Wellcome Found Enzyme inactivators
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
GB9020930D0 (en) 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
HU207524B (en) * 1991-11-22 1993-04-28 Mta Koezponti Kemiai Kutato In Industrial process for producing 5-alkyl-2'-deoxy-beta-uridines with stereoselective synthesis
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
ATE226093T1 (de) * 1991-11-26 2002-11-15 Isis Pharmaceuticals Inc Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
JP2823358B2 (ja) * 1992-05-26 1998-11-11 アルバータ リサーチ カウンスル 免疫抑制性および寛容原性修飾ルイス▲上ｃ▼およびＬａｃＮＡｃ化合物
CA2119315A1 (en) * 1993-03-18 1994-09-19 Tsujiaki Hata Nucleoside derivatives and anti-herpes composition
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
DK0747389T3 (da) * 1994-12-13 2004-01-26 Taiho Pharmaceutical Co Ltd 3'-substituerede nukleosidderivater
EP0876149A4 (en) * 1995-12-22 2001-09-26 Univ East Carolina METHOD FOR TREATING DISORDERS CHARACTERIZED BY A CYTIDINE DEAMINASE OR DESOXYCYTIDINE DEAMINASE
EP0878193A1 (en) * 1996-02-02 1998-11-18 Showa Shell Sekiyu K.K. Remedies for herpesvirus infection caused by herpesvirus and preventives for recurrence of the infection both containing triterpene derivatives as the active ingredient
CN1911237B (zh) * 1998-08-10 2010-09-15 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β-L-2＇-脱氧-核苷
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
CA2470938A1 (en) * 2001-12-20 2003-07-03 Raymond F. Schinazi Treatment of ebv and khsv infection and associated abnormal cellular proliferation
KR20070098798A (ko) 2004-12-03 2007-10-05 애드헤렉스 테크놀로지스 인크. Ｄｐｄ 억제제를 5-ｆｕ 및 5-ｆｕ 전구약물과 조합한투여방법
JP5669721B2 (ja) 2008-04-01 2015-02-12 バイオサーチ テクノロジーズ，インコーポレイテッド 安定化核酸ダーククエンチャー−フルオロフォアプローブ
CN101768197A (zh) * 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种奈拉滨的制备方法
US8658618B2 (en) 2009-10-14 2014-02-25 Adherex Technologies, Inc. Methods for preventing or reducing neurotoxicity associated with administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
DK3126517T3 (da) * 2014-03-30 2020-01-20 Cepheid Modificerede cytosin-polynukleotid-oligomere og fremgangsmåder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601020A (en) * 1978-04-24 1981-10-21 Stichting Grega Vzw 2'-deoxy-5 (2-halogenovinyl)-uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4274544A (en) * 1980-03-11 1981-06-23 The Continental Group, Inc. Single-piece plastic closure having integral seal forming means
EP0082667A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc Pharmaceutical compositions
EP0082668A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc 5-(2-Halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in treating viral infections
EP0095294A1 (en) * 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
EP0097039A1 (en) * 1982-06-16 1983-12-28 Beecham Group Plc 5-(E-2-halovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections
GB8517402D0 (en) * 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
DE3650741T2 (de) * 1985-09-17 2000-10-12 The Wellcome Foundation Ltd., Greenford Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds

Also Published As

Publication number Publication date
PT86356A (en) 1988-01-01
HU202112B (en) 1991-02-28
NO167576B (no) 1991-08-12
LT2064B (lt) 1993-06-15
EP0417560A1 (en) 1991-03-20
JPH0378370B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-12-13
EP0272065B1 (en) 1993-04-28
EP0486477A3 (en) 1992-06-17
RU2036199C1 (ru) 1995-05-27
EP0272065A3 (en) 1988-11-17
PT86356B (pt) 1990-11-07
PL277927A1 (en) 1989-08-21
PH24104A (en) 1990-03-05
MX9203216A (es) 1992-07-01
DK654287D0 (da) 1987-12-14
FI941523A7 (fi) 1994-03-31
PL160322B1 (pl) 1993-02-26
IL84810A (en) 1992-05-25
HU207735B (en) 1993-05-28
CS916187A2 (en) 1991-02-12
FI875487A7 (fi) 1988-06-16
ES2054693T3 (es) 1994-08-16
AU601529B2 (en) 1990-09-13
CS767588A3 (en) 1991-02-12
HU199867B (en) 1990-03-28
MC1882A1 (fr) 1989-01-24
DK169991A (da) 1991-10-04
AU5989090A (en) 1990-11-08
NO167576C (no) 1991-11-20
ATE88713T1 (de) 1993-05-15
DK654287A (da) 1988-06-16
HU200932B (en) 1990-09-28
LV5273A3 (lv) 1993-10-10
DE3785651D1 (de) 1993-06-03
CN87108265A (zh) 1988-07-13
FI875487A0 (fi) 1987-12-14
DE3785651T2 (de) 1993-11-11
FI941523A0 (fi) 1994-03-31
FI941523L (fi) 1994-03-31
AU8252187A (en) 1988-06-16
EP0272065A2 (en) 1988-06-22
CA1319143C (en) 1993-06-15
SU1731064A3 (ru) 1992-04-30
JPS63165397A (ja) 1988-07-08
HU903829D0 (en) 1990-11-28
IL95141A (en) 1992-05-25
CS342591A3 (en) 1992-04-15
PL277926A1 (en) 1989-08-21
US5079235A (en) 1992-01-07
PH24870A (en) 1990-12-26
PL160321B1 (pl) 1993-02-26
EP0486477A2 (en) 1992-05-20
DK168323B1 (da) 1994-03-14
DK169991D0 (da) 1991-10-04
GB8629892D0 (en) 1987-01-28
CS275402B6 (en) 1992-02-19
PL269462A1 (en) 1989-06-26
AU626041B2 (en) 1992-07-23
CN1080292A (zh) 1994-01-05
KR880007521A (ko) 1988-08-27
DD274766A5 (de) 1990-01-03
HUT46336A (en) 1988-10-28
PL158050B1 (pl) 1992-07-31
IL95141A0 (en) 1991-06-10
NO875209L (no) 1988-06-16
CS275398B2 (en) 1992-02-19
IL84810A0 (en) 1988-06-30
JPH03141292A (ja) 1991-06-17
NZ222898A (en) 1990-12-21
NO875209D0 (no) 1987-12-14
IE930471L (en) 1988-06-15
ZA879382B (en) 1989-08-30
IE930470L (en) 1988-06-15

Similar Documents

Publication Publication Date Title
DD264924A5 (de) Verfahren zur herstellung von pyrimidin-nucleosiden
DE69025529T2 (de) Weitere antivirale Pyrimidin-Nukleosiden
DE3855522T2 (de) Antivirale Verbindungen
DE68922903T2 (de) Antivirale Pyrimidin- und Purinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate.
DD282229A5 (de) Verfahren zur herstellung von therapeutischen acyclischen nucleosiden
DE69116750T2 (de) 9-Purinyl-Phosphonsäurederivate
DE3855333T2 (de) Therapeutische Nukleoside
DE3650492T2 (de) Therapeutische Nukleoside
DD202717A5 (de) Antivirale purinderivate und verfahren zu ihrer herstellung
DE2539963A1 (de) Purinverbindungen und ihre salze, sowie verfahren zu ihrer herstellung
DE3876174T2 (de) 2',3'-dideoxy-3'-fluorothymidin und verwandte verbindungen zur behandlung von adenovirus-infektionen.
EP0023594B1 (de) Trans-Chinazolinderivate, Verfahren zu ihrer Herstellung, Zwischenprodukte und Arzneimittel enthaltend solche Chinazolinderivate
DD261095A5 (de) Verfahren zur herstellung von antiviralen kombinationen
DE69527294T2 (de) 4-[2-amino-6-(cyclopropylamino)-9h-pyrin-9-yl]-2-cyclopenten-1-methanol-succinat als antivirales mittel
CH676712A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE69132052T2 (de) Uracil-reductase-inaktivator
DE3228060A1 (de) Verfahren zum behandeln von wuchernden hautkrankheiten
DE69128626T2 (de) Enzyminaktivatoren
DE68926697T2 (de) Ester von 9-(2-Hydroxyethoxymethyl)guanin
DE3872028T2 (de) Therapeutische nucleoside.
DE68914809T2 (de) Antivirale Wirkstoffe.
DD251984A5 (de) Verfahren zur herstellung von 3'-azidonucleosiden und pharmazeutisch vertraeglichen derivaten davon
DD287406A5 (de) Therapeutische nucleoside
US5028596A (en) 1-(β-D-arabinofuranosyl)-5-propynyluracil for treatment of VZV infections
DE2708827C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee